up to 48 weeks. RESULTS: At end of treatment, 73.5% of patients receiving BOT 0.5 mg twice daily and 75% receiving BOT 1.0 mg twice daily were in persistent remission compared with 4.4% of patients in the placebo group (P < .001 for both comparisons of BOT with placebo). Median time to relapse in the placebo group was 87 days. The frequency of adverse events was similar in the BOT and placebo groups. Morning serum levels of cortisol were in the normal range at baseline and did not significantly change during treatment. Four patients receiving BOT developed asymptomatic, low serum levels of cortisol. Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. CONCLUSIONS: In a phase 3 trial, up to 48 weeks of treatment with BOT (0.5 mg or 1.0 mg twice daily) was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well tolerated. EudraCT number; 2014-001485-99; ClinicalTrials.gov number, NCT02434029.

No abstract

No abstract

RATIONALE: Regular vigorous physical exercises in professional athletes may impact innate immune responses. METHODS: 37 young athletes, age 18-22 years were assessed for 4 months including 3 groups: G1-rowing, men (n 5 12); G2swimming, women (n 5 16); and G3-swimming, men (n 5 9). Leukocyte counts, neutrophil phagocytotic activity, and complement were assessed at the beginning of training and after 4 months of intensive training. RESULTS: Leukocyte counts rose in G1 by 3.49%, in G2 by 24.91%, and in G3 by 19.21%. Neutrophils also increased by 11.21% in G1, 28.5% (p<0.05) in G2, and 19.96% in G.3 Phagocytosing neutrophils rose in G1 by 9.76%, but fell in G2 by-12.46% (p<0.05), comprising 87.71% in G1, 64.23% in G2 and 63.33% in G3. Phagocytosed bacteria rose in G1 by 45.61% (p<0,05), but fell in G3 by-10.44% being 8.0661.39/ cell in G1, 7.4061.03/cell in G2 and 7.4162.45/cell in G3. Total number of phagocytosed bacteria increased in G1 by 68.79%, in G2 by 7.21% and G3 by 12.00%. Complement activity as CH50 fell in G1 by-20.41%, but rose in G2 by 21.10% and in G3 by 15.46% (p<0.05 for both). CONCLUSIONS: The influence of vigorous training on innate immunity in young athletes may depend on the sport discipline and, to less extent, on gender.

No abstract